##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 45 Download : 77

##plugins.themes.academic_pro.article.main##

Abstract

to study the possibilities of early prevention of CKD in patients with type 2 diabetes based on clinical and anamnestic data.

Keywords

anamnestic possibilities CKD

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Kholikov A.Yu, Begmatov B.B, Urmanova Yu.M, & Narziev V.Sh. (2024). “Possibilities of early prevention of chronic kidney disease in patients with type 2 diabetes mellitus based on clinical and anamnestic data”. Texas Journal of Medical Science, 29, 43–50. https://doi.org/10.62480/tjms.2024.vol29.pp43-50
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413–18.
  2. Fuller JH, Stevens LK, Wang SL, et al. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(suppl 2):S54–64.
  3. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32.
  4. de Boer IH, Rue TC, Hall YN. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532–9.doi:10.1001/jama.2011.861
  5. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-.doi:10.1056/NEJMoa1310799pmid:http://www.ncbi.nlm.nih.gov/pubmed/24738668
  6. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.doi:10.1016/j.diabres.2009.10.007
  7. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016;12:73-81.doi:10.1038/nrneph.2015.173
  8. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98:S1-115.doi:10.1016/j.kint.2020.06.019pmid:http://www.ncbi.nlm.nih.gov/pubmed/32998798
  9. American Diabetes Association. 11. microvascular complications and foot care: standards of medical care in Diabetes-2021. Diabetes Care 2021;44:S151-67.doi:10.2337/dc21-S011pmid:http://www.ncbi.nlm.nih.gov/pubmed/33298422
  10. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.doi:10.1056/NEJMoa0806470
  11. Schernthaner G, Schernthaner-Reiter MH. Therapy: risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol 2015;11:697-9.doi:10.1038/nrendo.2015.132pmid:http://www.ncbi.nlm.nih.gov/pubmed/26284445
  12. Kwon S, Kim YC, Park JY, et al. The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 2020;43:948–55.doi:10.2337/dc19-0936pmid:http://www.ncbi.nlm.nih.gov/pubmed/32132005
  13. Roumie CL, Chipman J, Min JY, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA 2019;322:1167-77.doi:10.1001/jama.2019.13206pmid:http://www.ncbi.nlm.nih.gov/pubmed/31536102
  14. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.doi:10.1001/archinternmed.2010.409pmid:http://www.ncbi.nlm.nih.gov/pubmed/21098347
  15. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.doi:10.1056/NEJMoa1515920
  16. Wanner C, Inzucchi SE, Zinman B, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG outcome trial. Diabetes Obes Metab 2020;22:2335-47.doi:10.1111/dom.14158pmid:http://www.ncbi.nlm.nih.gov/pubmed/32744354
  17. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.doi:10.1056/NEJMoa1812389pmid:http://www.ncbi.nlm.nih.gov/pubmed/30415602
  18. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.doi:10.1056/NEJMoa1811744